"The positivity rate increased with the PSA level from 67% for PSA <0.2 ng/ml to >90% for PSA >1.0 ng/ml (p < 0.05). Disease location also differed by PSA category, with prostate bed recurrence alone identified in 63% of positive cases with PSA <0.2 ng/ml, but <25% of cases with PSA >1.0 ng/ml, and distant metastases present in only 6% of positive cases with PSA <0.2 ng/ml versus >40% of cases with PSA >1.0 ng/ml. In the group with PSA <0.2 ng/ml, pelvic nodal disease without local recurrence was identified in 31% of cases"
There's still a lot of patients there with rising psa who aren't having disease found plus potentially some who have some tumours found but others missed. It's a shame the current trial putting Cu head to head with Ga isn't using these new scanners, that surely should be the next effort?
Will CU64 find even more tumours on the new scanners, keeping it's lead over the current diagnostics? Seems reasonable to think it would to at least some degree, higher uptake of drug with better scanning tech vs lower uptake of drug with better scanning tech.
CU6 Price at posting:
$4.54 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)